Eliana Clark

Eliana Clark, listed as chief executive, appears in our data through filings on Intellia Therapeutics, Inc. shares, published by SEC (Form 4). Over a trading history stretching from 1 March 2022 to 2 March 2026, the count stands at 22 filings.

Sales make up the whole of the open-market record (15 sales, €634k). Outside the open market, there are 6 share grants and 1 option exercise. 2026 to date brings no purchases and 2 sales.

The record was last updated on 3 March 2026 with an open-market sale (€7,113) in Intellia Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.